TABLE 3Differences in second-line therapies

TABLE 3aSummary of second-line treatments received by patients in the HR+/HER2+ population in the EGF3008 trial

aEGF3000849LAP + LET (n = 103)LET (n = 98)
Any medication (%)7874
Chemotherapy (%)5760
Hormone therapy (%)4433
TRA (%)1728
a

Data on second-line treatment were provided by the GlaxoSmithKline at the AG's request – the exact combinations of therapies are unknown.

b

In 82% of instances, it is known that TRA was provided in combination with chemotherapy.

TABLE 3bSummary of second-line treatments received by patients in the HR+/HER2+ population in the TANDEM trial

TAnDEM50TRA + ANAANA
Any medication (%)Not reportedNot reported
Chemotherapy (%) 832
TRAb (%) 170
Hormone therapy (%)Not reportedNot reported
a

Data on second-line treatment were provided by the GlaxoSmithKline at the AG's request – the exact combinations of therapies are unknown.

b

In 82% of instances, it is known that TRA was provided in combination with chemotherapy.

TABLE 3cSummary of second-line treatments received by patients in the HR+/HER2+ population in the eLEcTRA trial

eLEcTRA52TRA + LET (n = 26)LET (n = 31)
Any medication (%)Not reportedNot reported
Chemotherapy (%)Not reportedNot reported
TRA (%)3152
Hormone therapy (%)Not reportedNot reported
a

Data on second-line treatment were provided by the GlaxoSmithKline at the AG's request – the exact combinations of therapies are unknown.

b

In 82% of instances, it is known that TRA was provided in combination with chemotherapy.

From: 3, Assessment of clinical effectiveness

Cover of Lapatinib and Trastuzumab in Combination with an Aromatase Inhibitor for the First-Line Treatment of Metastatic Hormone Receptor-Positive Breast Cancer which Over-Expresses Human Epidermal Growth Factor 2 (HER2): A Systematic Review and Economic Analysis
Lapatinib and Trastuzumab in Combination with an Aromatase Inhibitor for the First-Line Treatment of Metastatic Hormone Receptor-Positive Breast Cancer which Over-Expresses Human Epidermal Growth Factor 2 (HER2): A Systematic Review and Economic Analysis.
Health Technology Assessment, No. 15.42.
Fleeman N, Bagust A, Boland A, et al.
Southampton (UK): NIHR Journals Library; 2011 Dec.
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.